کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5524180 1546240 2017 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
ترجمه فارسی عنوان
یک آزمایش فاز اول لانالیدومید بالا و ملپالان به عنوان تهویه مطبوع برای پیوند سلول های بنیادی اتولوگ در مبتلایان به مولتیپل میلوما چند ساله
کلمات کلیدی
لانالیدومید، ملپالان، پیوند سلول های بنیادی اتولوگ میلوم چندگانه تجربی و مقاوم،
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


- The maximum tolerated dose of high-dose lenalidomide was not reached at 350 mg/day.
- Pretransplantation conditioning with high-dose lenalidomide plus melphalan was well tolerated.
- All trial participants achieved a response to the investigational treatment strategy.
- Median progression-free and overall survival were 10 and 22 months, respectively.

Autologous stem cell transplantation (ASCT) conditioned with high-dose chemotherapy has long been established as the standard of care for eligible patients with newly diagnosed multiple myeloma. Despite recent therapeutic advances, high-dose melphalan (HDM) remains the chemotherapy regimen of choice in this setting. Lenalidomide (LEN) in combination with low-dose dexamethasone is recognized as a standard of care for patients with relapsed or refractory multiple myeloma (RRMM), and there is growing support for the administration of LEN as maintenance therapy post-ASCT. In view of the above, the present phase I clinical trial was designed to evaluate the safety and tolerability of high-dose LEN (HDLEN) in patients with RRMM, and to determine the maximum tolerated dose of HDLEN when added to HDM before ASCT. Despite administering HDLEN at doses of up to 350 mg/day, the maximum tolerated dose could not be determined, owing to an insufficient number of dose-limiting toxicities in the 21 patients enrolled in the trial. Conditioning with HDLEN plus HDM was associated with a favorable tolerability profile. Adverse events following ASCT were as expected with HDM. Median progression-free and overall survival were 10 months and 22 months, respectively, in this population of heavily pretreated patients. Our findings suggest that HDLEN in combination with HDM may offer significant potential as a conditioning regimen before ASCT in patients with RRMM. These preliminary findings are now being evaluated further in an ongoing phase II clinical trial.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 6, June 2017, Pages 930-937
نویسندگان
, , , , , , , , , , , , , , , ,